This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2014 Jun;28(6):1346-8.

doi: 10.1038/leu.2014.23. Epub 2014 Jan 14.

Improved long-term survival in multiple myeloma up to the age of 80 years

S Y Kristinsson¹, W F Anderson², O Landgren³

Affiliations

Affiliations

¹ 1] Division of Hematology, Department of Medicine, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden [2] Faculty of Medicine, University of Iceland and Department of Hematology, Landspitali National University Hospital, Reykjavik, Iceland.
² Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA.
³ Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.

PMID: 24418994
DOI: 10.1038/leu.2014.23

Improved long-term survival in multiple myeloma up to the age of 80 years

S Y Kristinsson et al. Leukemia. 2014 Jun.

. 2014 Jun;28(6):1346-8.

doi: 10.1038/leu.2014.23. Epub 2014 Jan 14.

Authors

S Y Kristinsson¹, W F Anderson², O Landgren³

Affiliations

¹ 1] Division of Hematology, Department of Medicine, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden [2] Faculty of Medicine, University of Iceland and Department of Hematology, Landspitali National University Hospital, Reykjavik, Iceland.
² Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA.
³ Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.

PMID: 24418994
DOI: 10.1038/leu.2014.23

No abstract available

PubMed Disclaimer

Similar articles

Early mortality in multiple myeloma.
Costa LJ, Gonsalves WI, Kumar SK. Costa LJ, et al. Leukemia. 2015 Jul;29(7):1616-8. doi: 10.1038/leu.2015.33. Epub 2015 Feb 12. Leukemia. 2015. PMID: 25673239 No abstract available.
Improved survival in multiple myeloma, with a diminishing racial gap and a widening socioeconomic status gap over three decades.
Sun T, Wang S, Sun H, Wen J, An G, Li J. Sun T, et al. Leuk Lymphoma. 2018 Jan;59(1):49-58. doi: 10.1080/10428194.2017.1335398. Epub 2017 Jun 9. Leuk Lymphoma. 2018. PMID: 28595471
Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data.
Pulte D, Gondos A, Brenner H. Pulte D, et al. Oncologist. 2011;16(11):1600-3. doi: 10.1634/theoncologist.2011-0229. Epub 2011 Oct 3. Oncologist. 2011. PMID: 21968047 Free PMC article.
Myeloma overview.
Soutar RL. Soutar RL. Scott Med J. 1998 Apr;43(2):38-41. doi: 10.1177/003693309804300203. Scott Med J. 1998. PMID: 9717201 Review. No abstract available.
Plasma Cell Myeloma - 20-Year Comparative Survival and Mortality of Three Plasma Cell Myeloma ICD-O-3 Oncologic Phenotypes by Age, Sex, Race, Stage, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 111,041 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).
Milano AF. Milano AF. J Insur Med. 2018;47(4):203-211. doi: 10.17849/insm-47-04-1-9.1. Epub 2019 Jan 22. J Insur Med. 2018. PMID: 30668210

See all similar articles

Cited by

The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study.
Oortgiesen BE, van Roon EN, Joosten P, Kibbelaar RE, Storm H, Hovenga S, van Rees B, Woolthuis G, Veeger N, de Waal EG, Hoogendoorn M. Oortgiesen BE, et al. Eur J Clin Pharmacol. 2017 Jun;73(6):771-778. doi: 10.1007/s00228-017-2227-1. Epub 2017 Mar 3. Eur J Clin Pharmacol. 2017. PMID: 28258356
Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries.
Olszewski AJ, Dusetzina SB, Trivedi AN, Davidoff AJ. Olszewski AJ, et al. J Clin Oncol. 2018 Oct 1;36(28):2879-2886. doi: 10.1200/JCO.2018.77.8894. Epub 2018 Aug 16. J Clin Oncol. 2018. PMID: 30113885 Free PMC article.
The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone.
Nakayama H, Aisa Y, Ito C, Sakurai A, Nakazato T. Nakayama H, et al. Hematol Rep. 2024 Sep 30;16(4):593-602. doi: 10.3390/hematolrep16040058. Hematol Rep. 2024. PMID: 39449301 Free PMC article.
Early mortality in multiple myeloma.
Costa LJ, Gonsalves WI, Kumar SK. Costa LJ, et al. Leukemia. 2015 Jul;29(7):1616-8. doi: 10.1038/leu.2015.33. Epub 2015 Feb 12. Leukemia. 2015. PMID: 25673239 No abstract available.
Cardiovascular-specific mortality among multiple myeloma patients: a population-based study.
Yin X, Fan F, Zhang B, Hu Y, Sun C. Yin X, et al. Ther Adv Hematol. 2022 Mar 31;13:20406207221086755. doi: 10.1177/20406207221086755. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35387110 Free PMC article.

See all "Cited by" articles

References

1. Blood. 2008 Mar 1;111(5):2516-20 - PubMed
1. N Engl J Med. 2007 Nov 22;357(21):2123-32 - PubMed
1. Blood. 2012 Aug 30;120(9):1754-6 - PubMed
1. Blood. 2012 Aug 30;120(9):1801-9 - PubMed
1. N Engl J Med. 2011 Mar 17;364(11):1046-60 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information